Clinical Trial Update: ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin [Phase 2]

View source ↗

Summary

Phase 2 study ACOU085 to prevent cisplatin-induced hearing loss in testicular cancer patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss
• Testicular Cancer

Drugs mentioned

• ACOU085

Snippet

Sponsor: Acousia Therapeutics GmbH | Conditions: Cisplatin-induced Hearing Loss | Phase 2 | Status: RECRUITING